ジェノタイピングアッセイ市場：2029年までの世界予測

Report Overview

At a CAGR of 13.8% over the course of the projection period, the genotyping assay market is expected to grow from USD 19.4 billion in 2024 to USD 37.1 billion in 2029.

ジェノタイピングアッセイ市場は、予測期間全体で 13.8% の CAGR で、2024 年の 194 億米ドルから 2029 年には 371 億米ドルに成長すると予想されます。

Advances in technology and falling DNA sequencing costs are anticipated to propel this market’s growth. Recently, the industry has grown at a slower rate due to the increased prevalence of hereditary illnesses. Additionally, the field of customized medicine and medication development has made genotyping a major component.

Opportunities in the market are anticipated to arise from the need for genome analysis in plants and animal livestock, an increasing emphasis on national sequencing programs aimed at establishing genetic connections with disease, and the expanding fields of applications for genotyping. On the other hand, market expansion may be somewhat hampered by the high cost of equipment.

“Reagents & Kits segment accounted for the highest CAGR”
By product & service, the market is primarily segmented into reagents and kits, instruments, GENOTYPING ASSAY services, and bioinformatics. The reagents & kits segment accounted for the largest share of the Genotyping assay in 2023. The availability of a broad variety of reagents, the rising demand for reagents due to the rising volume of GENOTYPING ASSAY tests conducted worldwide, and the comparatively lower initial outlay needed to implement reagents and kits for GENOTYPING Assay in pharmacies and diagnostic facilities are all responsible for this segment’s size.

“The polymerase chain reaction (PCR) segment accounted for the market share in the genotyping assay market, by technology, during the forecast period”
By technology, the market is primarily segmented into polymerase chain reaction (PCR), microarrays, capillary electrophoresis, sequencing, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF), and other technologies (in situ hybridization and allele-specific oligonucleotides). The PCR segment accounted for the largest share of the GENOTYPING ASSAY technology market in 2023. The main factors propelling the growth of the PCR market are the introduction of new technologies like reverse transcriptase PCR, nested PCR, hot-start PCR, allele-specific PCR, and multiplex PCR; technological developments in PCR instruments and reagents; and the growing use of PCR technologies in the domains of genetics, prenatal testing, forensics, and personalized medicine.

“Pharmacogenomics segment accounted for the highest share”
By application, the market is primarily segmented into pharmacogenomics, diagnostics & personalized medicine, agricultural biotechnology, animal genetics, and other applications. The pharmacogenomics segment accounted for the largest share of the GENOTYPING ASSAY applications market in 2023. The primary drivers of growth in this market are the growing need for pharmacogenomics to investigate adverse drug reactions (ADRs) in clinical trials and the requirement to lower the total cost of medication development for pharmaceutical companies. The growing need for customized medication, the rise in hereditary and life-threatening illnesses, and ongoing research into effective and alternative drug delivery strategies are all anticipated to fuel the growth of the pharmacogenomics genotyping test.

“Biopharmaceutical & pharmaceutical companies segment accounted for the highest share”
By end user, the market is primarily segmented into biopharmaceutical & pharmaceutical companies, diagnostic laboratories, academic & research institutes, and other end users. The biopharmaceutical & pharmaceutical companies segment accounted for the largest share of the GENOTYPING ASSAY end-user market in 2023. The growing need for pharmacogenomics in the medication development process, the introduction of new products, and FDA recommendations to incorporate pharmacogenomics studies and GENOTYPING ASSAY in the drug discovery process are all responsible for this segment’s size. Furthermore, the expansion of this market sector within GENOTYPING ASSAY is further facilitated by a rise in partnerships and funding for pharmacogenomics research.

“Asia Pacific: The fastest-growing region in cancer biomarkers market”
The global cancer biomarkers market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa and GCC Countries. The Asia Pacific region is projected to register the highest CAGR during the forecast period, primarily due to the increasing financial support from public as well as private agencies, increasing number of NGS-based research projects, increasing awareness about precision medicine, and high incidence of chronic diseases.

Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level (27%), Director-level (18%), and Others (55%)
• By Region: North America (51%), Europe (21%), Asia- Pacific (18%), Latin America (6%), and Middle East & Africa(4%)

Lists of Companies Profiled in the Report:

• Thermo Fisher Scientific Inc. (US),
• Illumina, Inc. (US),
• Danaher Corporation (US),
• QIAGEN (Netherlands),
• Eurofins Scientific (Luxembourg),
• F. Hoffmann-La Roche Ltd. (Switzerland),
• Bio-Rad Laboratories, Inc. (US),
• Merck KGAA (Germany),
• Agilent Technologies (US),
• Revvity Inc. (US),
• Standard Bio Tools (US),
• PacBio (US),
• GENEWIZ Inc. (US),
• Luminex Corporation (Diasorin Company) (US),
• Oxford Nanopore Technologies Plc (UK),
• GenScript (US),
• Takara Bio Inc. (Japan),
• New England Biolabs (US),
• Promega Corporation (US),
• Tecan Trading AG (Switzerland),
• Genotypic Technology Pvt. Ltd. (India),
• BGI GROUP (China),
• Novogene Co., Ltd. (China),
• Paragon Genomics, Inc. (US),
• NeoGenomics Laboratories (US).
Research Coverage
This research report categorizes the genotyping assay market by product & services, technology, application, end-user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the optometry equipment market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the genotyping assay market. Competitive analysis of upcoming startups in the optometry equipment market ecosystem is covered in this report.
Reasons to buy this report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall genotyping assay market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (Technological advancements and reduced prices of DNA sequencing, Growing importance and use of genotyping in drug discovery and development), restraints (High manufacturing, installation, and maintenance costs of genotyping instruments), opportunities (Increasing application areas in genomics and genotyping analysis for animal genetics and agricultural biotechnology), and challenges (lack of adequate data management in genomics research) influencing the growth of the genotyping assay market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the genotyping assay market
• Market Development: Comprehensive information about lucrative markets – the report analyses the genotyping assay market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the genotyping assay market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Danaher Corporation (US), Eurofins Scientific (Luxembourg), and QIAGEN (Netherlands). among others in genotyping assay market.

Table of Contents

1            INTRODUCTION            51

1.1         STUDY OBJECTIVES      51

1.2         MARKET DEFINITION   51

1.2.1      INCLUSIONS & EXCLUSIONS     52

TABLE 1             GENOTYPING ASSAY MARKET: INCLUSIONS & EXCLUSIONS              52

1.3         STUDY SCOPE  53

1.3.1      SEGMENTS COVERED   53

FIGURE 1           GENOTYPING ASSAY MARKET: SEGMENTS COVERED   53

1.3.2      REGIONS COVERED      54

FIGURE 2           GENOTYPING ASSAY MARKET: REGIONS COVERED       54

1.3.3      YEARS CONSIDERED     54

FIGURE 3           GENOTYPING ASSAY MARKET: YEARS CONSIDERED     54

1.3.4      CURRENCY CONSIDERED          54

1.4         STAKEHOLDERS            55

1.5         SUMMARY OF CHANGES            55

1.5.1      RECESSION IMPACT      56

2            RESEARCH METHODOLOGY     57

2.1         RESEARCH DATA           57

FIGURE 4           GENOTYPING ASSAY MARKET: RESEARCH DESIGN        57

2.1.1      SECONDARY DATA       58

2.1.1.1   Key secondary sources       58

2.1.1.2   Key data from secondary sources     59

FIGURE 5           KEY DATA FROM SECONDARY SOURCES            59

2.1.1.3   Objectives of secondary research     59

2.1.2      PRIMARY DATA 60

2.1.2.1   Key primary sources: Demand and supply sides           60

FIGURE 6           KEY PRIMARY SOURCES: DEMAND AND SUPPLY SIDES 60

2.1.2.2   Objectives of primary research         60

2.1.2.3   Key data from primary sources         61

TABLE 2             GENOTYPING ASSAY MARKET: KEY DATA FROM PRIMARY SOURCES           61

2.1.2.4   Insights from primary experts          62

FIGURE 7           GENOTYPING ASSAY MARKET: KEY INSIGHTS FROM PRIMARY EXPERTS           62

2.1.2.5   Breakdown of primaries     62

FIGURE 8           BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 62

FIGURE 9           BREAKDOWN OF PRIMARIES: BY COMPANY TYPE, DESIGNATION, AND REGION    63

2.2         MARKET SIZE ESTIMATION       63

2.2.1      BOTTOM-UP APPROACH           63

2.2.1.1   Company revenue estimation approach         64

FIGURE 10         COMPANY REVENUE ESTIMATION APPROACH 64

2.2.1.2   Company presentations and primary interviews           64

2.2.1.3   Growth forecasts 64

2.2.1.4   CAGR projections             65

FIGURE 11         CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS   65

2.2.2      TOP-DOWN APPROACH             65

FIGURE 12         GENOTYPING ASSAY MARKET: TOP-DOWN APPROACH              66

2.3         MARKET BREAKDOWN AND DATA TRIANGULATION    66

FIGURE 13         GENOTYPING ASSAY MARKET: DATA TRIANGULATION METHODOLOGY           67

2.4         MARKET SHARE ANALYSIS         67

2.5         STUDY ASSUMPTIONS  68

2.6         GROWTH RATE ASSUMPTIONS 68

2.7         RISK ASSESSMENT         68

TABLE 3             GENOTYPING ASSAY MARKET: RISK ASSESSMENT         68

2.8         RESEARCH LIMITATIONS           69

2.9         IMPACT OF ECONOMIC RECESSION ON GENOTYPING ASSAY MARKET              69

3            EXECUTIVE SUMMARY 71

FIGURE 14         GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2024 VS. 2029 (USD MILLION)             71

FIGURE 15         GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2024 VS. 2029 (USD MILLION)             72

FIGURE 16         GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2024 VS. 2029 (USD MILLION)     72

FIGURE 17         GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION) 73

FIGURE 18         GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2024 VS. 2029 (USD MILLION)        74

FIGURE 19         GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2024 VS. 2029 (USD MILLION)     74

FIGURE 20         GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE,  2024 VS. 2029 (USD MILLION)    75

FIGURE 21         GENOTYPING ASSAY MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 76

FIGURE 22         GENOTYPING ASSAY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 76

FIGURE 23         GENOTYPING ASSAY MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)          77

4            PREMIUM INSIGHTS      78

4.1         GENOTYPING ASSAY MARKET OVERVIEW         78

FIGURE 24         TECHNOLOGICAL ADVANCEMENTS AND REDUCED PRICES OF DNA SEQUENCING TO DRIVE MARKET         78

4.2         GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2024 VS. 2029              79

FIGURE 25         REAGENTS & KITS TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD     79

4.3         GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2024 VS. 2029 79

FIGURE 26         POLYMERASE CHAIN REACTION TO POSSESS LARGEST MARKET SHARE BETWEEN 2024 AND 2029          79

4.4         GENOTYPING ASSAY MARKET, BY APPLICATION, 2024 VS. 2029 80

FIGURE 27         PHARMACOGENOMICS TO ACCOUNT FOR LARGEST MARKET SHARE DURING STUDY PERIOD             80

4.5         GENOTYPING ASSAY MARKET, BY END USER, 2024 VS. 2029        80

FIGURE 28         PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO COMMAND LARGEST MARKET SHARE FROM 2024 TO 2029         80

4.6         GENOTYPING ASSAY MARKET: REGIONAL GROWTH OPPORTUNITIES (2024–2029)       81

FIGURE 29         ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD       81

5            MARKET OVERVIEW     82

5.1         INTRODUCTION            82

5.2         MARKET DYNAMICS     82

FIGURE 30         GENOTYPING ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,  AND CHALLENGES 82

5.2.1      DRIVERS            83

5.2.1.1   Technological advancements and reduced prices of DNA sequencing      83

FIGURE 31         COST OF HUMAN WHOLE-GENOME SEQUENCING, 2002–2022              83

5.2.1.2   Increasing incidence of genetic diseases and rising use of personalized medicines              84

5.2.1.3   Growing importance and use of genotyping in drug discovery and development              84

5.2.1.4   Increasing demand for bioinformatics solutions in data analysis 85

5.2.2      RESTRAINTS     85

5.2.2.1   High manufacturing, installation, and maintenance costs of genotyping instruments          85

5.2.3      OPPORTUNITIES           86

5.2.3.1   Increasing use of genomics in animal genetics and agricultural biotechnology              86

5.2.4      CHALLENGES   87

5.2.4.1   Lack of adequate data management in genomics research          87

5.2.4.2   Dearth of trained healthcare personnel for genomic sequencing data analysis              88

5.3         PRICING ANALYSIS        88

5.3.1      PRICING ANALYSIS FOR GENOTYPING ASSAY PRODUCTS,  2021–2023              88

TABLE 4             PRICING ANALYSIS TREND FOR GENOTYPING ASSAY PRODUCTS, 2021–2023  88

5.3.2      AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS,  BY REGION, 2021–2023        89

TABLE 5             AVERAGE SELLING PRICE OF GENOTYPING ASSAY PRODUCTS, BY REGION, 2021–2023  89

5.4         PATENT ANALYSIS        90

FIGURE 32         PATENT APPLICATIONS FOR GENOTYPING ASSAY (NEXT-GENERATION SEQUENCING) MARKET, JANUARY 2012–MARCH 2023       90

TABLE 6             INDICATIVE LIST OF PATENTS IN GENOTYPING ASSAY (NEXT-GENERATION SEQUENCING) MARKET 91

5.5         VALUE CHAIN ANALYSIS            91

FIGURE 33         GENOTYPING ASSAY MARKET: VALUE CHAIN ANALYSIS              92

5.6         SUPPLY CHAIN ANALYSIS          92

5.6.1      PROMINENT COMPANIES          92

5.6.2      SMALL & MEDIUM-SIZED ENTERPRISES 92

5.6.3      END USERS       93

FIGURE 34         GENOTYPING ASSAY MARKET: SUPPLY CHAIN ANALYSIS              93

5.7         ECOSYSTEM ANALYSIS 93

FIGURE 35         GENOTYPING ASSAY MARKET: ECOSYSTEM MAP           94

5.7.1      ROLE IN ECOSYSTEM    94

TABLE 7             GENOTYPING ASSAY MARKET: ROLE IN ECOSYSTEM    94

5.8         PORTER’S FIVE FORCES ANALYSIS         95

FIGURE 36         GENOTYPING ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS          95

TABLE 8             GENOTYPING ASSAY MARKET: PORTER’S FIVE FORCES ANALYSIS          95

5.8.1      THREAT OF NEW ENTRANTS    96

5.8.2      THREAT OF SUBSTITUTES         96

5.8.3      BARGAINING POWER OF SUPPLIERS     96

5.8.4      BARGAINING POWER OF BUYERS           96

5.8.5      INTENSITY OF COMPETITIVE RIVALRY 96

5.9         KEY STAKEHOLDERS AND BUYING CRITERIA    97

5.9.1      KEY STAKEHOLDERS IN BUYING PROCESS         97

FIGURE 37         INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS              97

TABLE 9             INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS              97

5.9.2      KEY BUYING CRITERIA 98

FIGURE 38         KEY BUYING CRITERIA FOR GENOTYPING ASSAYS         98

TABLE 10           KEY BUYING CRITERIA FOR GENOTYPING ASSAYS         98

5.10       REGULATORY ANALYSIS            99

5.10.1    REGULATORY LANDSCAPE       99

5.10.1.1 North America     99

5.10.1.1.1            US         99

TABLE 11           US FDA: MEDICAL DEVICE CLASSIFICATION     100

TABLE 12           US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS              100

5.10.1.1.2            Canada  100

5.10.1.2 Europe  100

5.10.1.3 Asia Pacific          101

5.10.1.3.1            China     101

TABLE 13           CHINA: CLASSIFICATION OF MEDICAL DEVICES             101

5.10.1.3.2            Japan     102

5.10.1.3.3            India      102

5.10.1.4 Latin America      102

5.10.1.5 Middle East         102

5.11       TRADE ANALYSIS          103

5.11.1    IMPORT DATA FOR PCR ANALYZERS (HS CODE 3822)    103

TABLE 14           IMPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD)       103

5.11.2    EXPORT DATA FOR PCR ANALYZERS (HS CODE 3822)    103

TABLE 15           EXPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD)       103

5.12       TECHNOLOGY ANALYSIS           104

5.12.1    KEY TECHNOLOGIES    104

5.12.1.1 Polymerase chain reaction 104

5.12.1.2 Next-generation sequencing            104

5.12.2    COMPLEMENTARY TECHNOLOGIES     104

5.12.2.1 CRISPR-based perturbational         104

5.12.3    ADJACENT TECHNOLOGIES      104

5.12.3.1 Single-cell RNA sequencing             104

5.13       KEY CONFERENCES AND EVENTS, 2024–2025     105

TABLE 16           GENOTYPING ASSAY  MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024–DECEMBER 2025  105

5.14       TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 106

FIGURE 39         REVENUE SHIFT IN GENOTYPING ASSAY MARKET         106

5.15       CASE STUDY ANALYSIS 106

5.15.1    DIGITAL PCR FOR GENOTYPE QUANTIFICATION IN PASTA PRODUCTION CHAIN   106

5.16       INVESTMENT & FUNDING SCENARIO    107

6            GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE            108

6.1         INTRODUCTION            109

TABLE 17           GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)     109

6.2         REAGENTS & KITS          109

6.2.1      INCREASING VOLUME OF GENOTYPING TESTS TO DRIVE MARKET              109

TABLE 18           GENOTYPING ASSAY REAGENTS & KITS MARKET, BY REGION,  2022–2029 (USD MILLION)          110

TABLE 19           NORTH AMERICA: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      110

TABLE 20           EUROPE: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 111

TABLE 21          ASIA PACIFIC: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         111

TABLE 22           LATIN AMERICA: GENOTYPING ASSAY REAGENTS & KITS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      112

6.3         GENOTYPING SERVICES            112

6.3.1      RISING DEMAND FOR SEQUENCING FROM HOSPITALS AND PHARMACEUTICAL COMPANIES TO PROPEL MARKET GROWTH            112

TABLE 23           GENOTYPING ASSAY SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)     113

TABLE 24           NORTH AMERICA: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 113

TABLE 25           EUROPE: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 114

TABLE 26           ASIA PACIFIC: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 114

TABLE 27           LATIN AMERICA: GENOTYPING ASSAY SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 115

6.4         INSTRUMENTS 115

TABLE 28           GENOTYPING ASSAY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)          115

TABLE 29           NORTH AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      116

TABLE 30           EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 116

TABLE 31           ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         116

TABLE 32           LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      117

TABLE 33           GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION)          117

6.4.1      SEQUENCERS & AMPLIFIERS     117

6.4.1.1   Decreasing cost of DNA sequencing procedures to aid market growth     117

TABLE 34           GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY REGION,  2022–2029 (USD MILLION)     118

TABLE 35           NORTH AMERICA: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)           118

TABLE 36           EUROPE: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      119

TABLE 37           ASIA PACIFIC: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)           119

TABLE 38           LATIN AMERICA: GENOTYPING ASSAY SEQUENCERS & AMPLIFIERS MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)           120

6.4.2      ANALYZERS      120

6.4.2.1   Technological advancements in high-throughput analyzers to support market growth   120

TABLE 39           GENOTYPING ASSAY ANALYZERS MARKET, BY REGION, 2022–2029 (USD MILLION)     121

TABLE 40           NORTH AMERICA: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         121

TABLE 41           EUROPE: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 122

TABLE 42           ASIA PACIFIC: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 122

TABLE 43           LATIN AMERICA: GENOTYPING ASSAY ANALYZERS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         123

6.5         BIOINFORMATICS         123

TABLE 44           GENOTYPING ASSAY BIOINFORMATICS MARKET, BY REGION, 2022–2029, (USD MILLION)         123

TABLE 45           NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      124

TABLE 46           EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 124

TABLE 47           ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      125

TABLE 48           LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      125

TABLE 49           GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE, 2022–2029 (USD MILLION)          125

6.5.1      SOFTWARE       126

6.5.1.1   High volume of sequencing and microarray tests to augment segment growth              126

TABLE 50           GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY REGION,  2022–2029 (USD MILLION)             126

TABLE 51           NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)             127

TABLE 52           EUROPE: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      127

TABLE 53           ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET, BY COUNTRY,  2022–2029 (USD MILLION)             127

TABLE 54           LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS SOFTWARE MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)             128

6.5.2      SERVICES          128

6.5.2.1   Increasing public-private funding to support segment growth    128

TABLE 55           GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)     129

TABLE 56           NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)  129

TABLE 57           EUROPE: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      130

TABLE 58           ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     130

TABLE 59           LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     131

7            GENOTYPING ASSAY MARKET, BY TECHNOLOGY          132

7.1         INTRODUCTION            133

TABLE 60           GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 133

7.2         POLYMERASE CHAIN REACTION            133

TABLE 61           COMPARATIVE STUDY: REAL-TIME POLYMERASE CHAIN REACTION VS. DIGITAL POLYMERASE CHAIN REACTION           134

TABLE 62           GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE,  2022–2029 (USD MILLION)           135

TABLE 63           GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY REGION,  2022–2029 (USD MILLION)      135

TABLE 64           NORTH AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION,  BY COUNTRY, 2022–2029 (USD MILLION)              135

TABLE 65           EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION,  BY COUNTRY, 2022–2029 (USD MILLION)   136

TABLE 66           ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION,  BY COUNTRY, 2022–2029 (USD MILLION)              136

TABLE 67           LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION,  BY COUNTRY, 2022–2029 (USD MILLION)              137

7.2.1      REAL-TIME POLYMERASE CHAIN REACTION     137

7.2.1.1   Continuous automation of laboratory techniques to propel market growth              137

TABLE 68           KEY REAL-TIME POLYMERASE CHAIN REACTION PRODUCTS              137

TABLE 69           REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY REGION,  2022–2029 (USD MILLION)     139

TABLE 70           NORTH AMERICA: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 139

TABLE 71           EUROPE: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      140

TABLE 72           ASIA PACIFIC: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      140

TABLE 73           LATIN AMERICA: REAL-TIME POLYMERASE CHAIN REACTION MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      141

7.2.2      DIGITAL POLYMERASE CHAIN REACTION         141

7.2.2.1   High cost of instruments and lack of knowledge among end users to limit market growth   141

TABLE 74           KEY DIGITAL POLYMERASE CHAIN REACTION PRODUCTS              141

TABLE 75           DIGITAL POLYMERASE CHAIN REACTION MARKET, BY REGION,  2022–2029 (USD MILLION)     142

TABLE 76           NORTH AMERICA: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      142

TABLE 77           EUROPE: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         143

TABLE 78           ASIA PACIFIC: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      143

TABLE 79           LATIN AMERICA: DIGITAL POLYMERASE CHAIN REACTION MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      144

7.3         MICROARRAYS 144

7.3.1      HIGH DEMAND FOR PERSONALIZED MEDICINES TO DRIVE MARKET              144

TABLE 80           KEY MICROARRAYS       145

TABLE 81          GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY REGION,  2022–2029 (USD MILLION)          146

TABLE 82           NORTH AMERICA: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY,  2022–2029 (USD MILLION)         146

TABLE 83           EUROPE: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY,  2022–2029 (USD MILLION)         147

TABLE 84           ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY,  2022–2029 (USD MILLION)         147

TABLE 85           LATIN AMERICA: GENOTYPING ASSAY MARKET FOR MICROARRAYS, BY COUNTRY,  2022–2029 (USD MILLION)         148

7.4         SEQUENCING   148

TABLE 86           GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)          148

TABLE 87           GENOTYPING ASSAY MARKET FOR SEQUENCING, BY REGION, 2022–2029 (USD MILLION)          149

TABLE 88           NORTH AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY,  2022–2029 (USD MILLION)           149

TABLE 89           EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY,  2022–2029 (USD MILLION) 150

TABLE 90           ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY,  2022–2029 (USD MILLION)           150

TABLE 91           LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY COUNTRY,  2022–2029 (USD MILLION)           151

7.4.1      NEXT-GENERATION SEQUENCING        151

7.4.1.1   Higher speed and better accuracy to fuel segment growth          151

TABLE 92           KEY NEXT-GENERATION SEQUENCING PRODUCTS       152

TABLE 93           NEXT-GENERATION SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)     153

TABLE 94          NORTH AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         153

TABLE 95           EUROPE: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 154

TABLE 96           ASIA PACIFIC: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 154

TABLE 97           LATIN AMERICA: NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)         155

7.4.2      PYROSEQUENCING       155

7.4.2.1   Growing need for genotyping difficult assays with accurate results to augment growth   155

TABLE 98           KEY PYROSEQUENCING PRODUCTS      155

TABLE 99           PYROSEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)          156

TABLE 100         NORTH AMERICA: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          156

TABLE 101         EUROPE: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     157

TABLE 102         ASIA PACIFIC: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          157

TABLE 103         LATIN AMERICA: PYROSEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          157

7.4.3      SANGER SEQUENCING 158

7.4.3.1   Increasing use in small-scale experiments to boost segment growth          158

TABLE 104         KEY SANGER SEQUENCING PRODUCTS 158

TABLE 105         SANGER SEQUENCING MARKET, BY REGION, 2022–2029 (USD MILLION)          159

TABLE 106         NORTH AMERICA: SANGER SEQUENCING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 159

TABLE 107         EUROPE: SANGER SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     160

TABLE 108         ASIA PACIFIC: SANGER SEQUENCING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          160

TABLE 109         LATIN AMERICA: SANGER SEQUENCING MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 160

7.5         CAPILLARY ELECTROPHORESIS             161

TABLE 110         GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE,  2022–2029 (USD MILLION)         161

TABLE 111         GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY REGION,  2022–2029 (USD MILLION)    162

TABLE 112         NORTH AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS,  BY COUNTRY, 2022–2029 (USD MILLION)              162

TABLE 113         EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY COUNTRY,  2022–2029 (USD MILLION) 163

TABLE 114         ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS,  BY COUNTRY, 2022–2029 (USD MILLION) 163

TABLE 115         LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS,  BY COUNTRY, 2022–2029 (USD MILLION)              164

7.5.1      AMPLIFIED FRAGMENT LENGTH POLYMORPHISM        164

7.5.1.1   Increasing use in determining genetic differences to drive segment          164

TABLE 116         AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY REGION,  2022–2029 (USD MILLION)             165

TABLE 117         NORTH AMERICA: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)   165

TABLE 118         EUROPE: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      166

TABLE 119         ASIA PACIFIC: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY,  2022–2029 (USD MILLION)   166

TABLE 120         LATIN AMERICA: AMPLIFIED FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY,  2022–2029 (USD MILLION)   167

7.5.2      RESTRICTION FRAGMENT LENGTH POLYMORPHISM   167

7.5.2.1   Rising demand in forensics and agricultural institutions to support market growth              167

TABLE 121         KEY RESTRICTION FRAGMENT LENGTH POLYMORPHISM PRODUCTS       167

TABLE 122        RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY REGION,  2022–2029 (USD MILLION)             168

TABLE 123         NORTH AMERICA: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)   168

TABLE 124         EUROPE: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      169

TABLE 125         ASIA PACIFIC: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET, BY COUNTRY,  2022–2029 (USD MILLION)   169

TABLE 126         LATIN AMERICA: RESTRICTION FRAGMENT LENGTH POLYMORPHISM MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)   170

7.5.3      SINGLE-STRAND CONFORMATION POLYMORPHISM    170

7.5.3.1   Increasing applications in virology to boost segment growth       170

TABLE 127         KEY SINGLE-STRAND CONFORMATION POLYMORPHISM PRODUCTS       170

TABLE 128         SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY REGION,  2022–2029 (USD MILLION)             171

TABLE 129         NORTH AMERICA: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)   171

TABLE 130         EUROPE: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY,  2022–2029 (USD MILLION)      172

TABLE 131         ASIA PACIFIC: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET, BY COUNTRY,  2022–2029 (USD MILLION)   172

TABLE 132         LATIN AMERICA: SINGLE-STRAND CONFORMATION POLYMORPHISM MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)   173

7.6         MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY 173

7.6.1      INCREASING APPLICATIONS IN CLINICAL DIAGNOSTICS AND PHARMACOGENOMICS TO AID MARKET GROWTH        173

TABLE 133         KEY MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT PRODUCTS    173

TABLE 134         GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION)       174

TABLE 135         NORTH AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY,  2022–2029 (USD MILLION)      174

TABLE 136         EUROPE: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY,  2022–2029 (USD MILLION)      175

TABLE 137         ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY,  2022–2029 (USD MILLION)      175

TABLE 138         LATIN AMERICA: GENOTYPING ASSAY MARKET FOR MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT MASS SPECTROMETRY, BY COUNTRY,  2022–2029 (USD MILLION)      176

7.7         OTHER TECHNOLOGIES            176

TABLE 139         OTHER GENOTYPING TECHNOLOGIES 176

TABLE 140         GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION,  2022–2029 (USD MILLION)             177

TABLE 141         NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES,  BY COUNTRY, 2022–2029 (USD MILLION)      177

TABLE 142         EUROPE: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,  2022–2029 (USD MILLION)      178

TABLE 143         ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,  2022–2029 (USD MILLION)      178

TABLE 144         LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,  2022–2029 (USD MILLION)      179

8            GENOTYPING ASSAY MARKET, BY APPLICATION           180

8.1         INTRODUCTION            181

TABLE 145         GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 181

8.2         PHARMACOGENOMICS 181

8.2.1      GROWING DEMAND FOR STUDYING ADVERSE DRUG REACTIONS IN CLINICAL TRIALS TO DRIVE MARKET   181

TABLE 146         GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY REGION,  2022–2029 (USD MILLION)     182

TABLE 147         NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS,  BY COUNTRY, 2022–2029 (USD MILLION)        182

TABLE 148         EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY,  2022–2029 (USD MILLION)        183

TABLE 149         ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY,  2022–2029 (USD MILLION)        183

TABLE 150         LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACOGENOMICS, BY COUNTRY,  2022–2029 (USD MILLION)        184

8.3         DIAGNOSTICS & PERSONALIZED MEDICINES    184

8.3.1      INCREASING FOCUS ON DEVELOPING DIAGNOSTICS TESTS THROUGH RAPID GENOTYPING TO AID MARKET GROWTH      184

TABLE 151         GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY REGION, 2022–2029 (USD MILLION)      185

TABLE 152         NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)          185

TABLE 153         EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)  186

TABLE 154         ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)          186

TABLE 155         LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTICS & PERSONALIZED MEDICINES, BY COUNTRY, 2022–2029 (USD MILLION)          187

8.4         ANIMAL GENETICS       187

8.4.1      NEED TO INCREASE LIVESTOCK POPULATION TO PROPEL MARKET GROWTH          187

TABLE 156         GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY REGION,  2022–2029 (USD MILLION)     188

TABLE 157         NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY,  2022–2029 (USD MILLION)   188

TABLE 158         EUROPE: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS BY COUNTRY,  2022–2029 (USD MILLION)    189

TABLE 159         ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY,  2022–2029 (USD MILLION)   189

TABLE 160         LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ANIMAL GENETICS, BY COUNTRY,  2022–2029 (USD MILLION)   190

8.5         AGRICULTURAL BIOTECHNOLOGY      190

8.5.1      INCREASING USE OF PLANT GENOTYPING IN RESEARCH LABORATORIES AND GREENHOUSES TO FUEL MARKET GROWTH        190

TABLE 161         GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY, BY REGION,  2022–2029 (USD MILLION)      191

TABLE 162         NORTH AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY,  BY COUNTRY, 2022–2029 (USD MILLION)              191

TABLE 163         EUROPE: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY,  BY COUNTRY, 2022–2029 (USD MILLION)   192

TABLE 164         ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY  BY COUNTRY, 2022–2029 (USD MILLION)              192

TABLE 165         LATIN AMERICA: GENOTYPING ASSAY MARKET FOR AGRICULTURAL BIOTECHNOLOGY,  BY COUNTRY, 2022–2029 (USD MILLION)              193

8.6         OTHER APPLICATIONS 193

TABLE 166         GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY REGION,  2022–2029 (USD MILLION)     193

TABLE 167         NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2022–2029 (USD MILLION)        194

TABLE 168         EUROPE: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS BY COUNTRY,  2022–2029 (USD MILLION)         194

TABLE 169         ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2022–2029 (USD MILLION)        194

TABLE 170         LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY,  2022–2029 (USD MILLION)        195

9            GENOTYPING ASSAY MARKET, BY END USER     196

9.1         INTRODUCTION            197

TABLE 171         GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)          197

9.2         PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES        197

9.2.1      RISING DEMAND FOR PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET           197

TABLE 172         GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)              198

TABLE 173         NORTH AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029(USD MILLION)           198

TABLE 174         EUROPE: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029(USD MILLION)           199

TABLE 175         ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)          199

TABLE 176         LATIN AMERICA: GENOTYPING ASSAY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)          200

9.3         DIAGNOSTIC LABORATORIES   200

9.3.1      GROWING PREFERENCE FOR PERSONALIZED MEDICINES TO AUGMENT MARKET GROWTH  200

TABLE 177         GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION,  2022–2029 (USD MILLION)           201

TABLE 178         NORTH AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES,  BY COUNTRY, 2022–2029(USD MILLION)              201

TABLE 179         EUROPE: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY,  2022–2029 (USD MILLION)       202

TABLE 180         ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES,  BY COUNTRY, 2022–2029 (USD MILLION)       202

TABLE 181         LATIN AMERICA: GENOTYPING ASSAY MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)              203

9.4         ACADEMIC & RESEARCH INSTITUTES   203

9.4.1      INCREASING INDUSTRY-ACADEMIA COLLABORATIONS FOR DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH          203

TABLE 182         GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION,  2022–2029 (USD MILLION)   204

TABLE 183         NORTH AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)              204

TABLE 184         EUROPE: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY COUNTRY, 2022–2029 (USD MILLION)        205

TABLE 185         ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)          205

TABLE 186         LATIN AMERICA: GENOTYPING ASSAY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)              206

9.5         OTHER END USERS        206

TABLE 187         GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY REGION,  2022–2029 (USD MILLION)     207

TABLE 188         NORTH AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY,  2022–2029 (USD MILLION) 207

TABLE 189         EUROPE: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY,  2022–2029 (USD MILLION)          208

TABLE 190         ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY,  2022–2029 (USD MILLION)          208

TABLE 191         LATIN AMERICA: GENOTYPING ASSAY MARKET FOR OTHER END USERS, BY COUNTRY,  2022–2029 (USD MILLION) 209

10          GENOTYPING ASSAY MARKET, BY REGION        210

10.1       INTRODUCTION            211

TABLE 192         GENOTYPING ASSAY MARKET, BY REGION, 2022–2029 (USD MILLION)          211

10.2       NORTH AMERICA          211

FIGURE 40         NORTH AMERICA: GENOTYPING ASSAY MARKET SNAPSHOT              212

TABLE 193         NORTH AMERICA: GENOTYPING ASSAY MARKET, BY COUNTRY,  2022–2029 (USD MILLION) 212

TABLE 194         NORTH AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)         213

TABLE 195         NORTH AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION) 213

TABLE 196         NORTH AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION) 213

TABLE 197         NORTH AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY,  2022–2029 (USD MILLION)       214

TABLE 198         NORTH AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION,  BY TYPE, 2022–2029 (USD MILLION) 214

TABLE 199         NORTH AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)      215

TABLE 200         NORTH AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS,  BY TYPE, 2022–2029 (USD MILLION)  215

TABLE 201         NORTH AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        216

TABLE 202         NORTH AMERICA: GENOTYPING ASSAY MARKET, BY END USER,  2022–2029 (USD MILLION)          216

10.2.1    US         217

10.2.1.1 US to dominate North American genotyping assay market during forecast period              217

TABLE 203         US: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)          217

TABLE 204         US: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)          218

TABLE 205         US: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION)          218

TABLE 206         US: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)     218

TABLE 207         US: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE,  2022–2029 (USD MILLION)           219

TABLE 208         US: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)          219

TABLE 209         US: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE,  2022–2029 (USD MILLION)         219

TABLE 210         US: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 220

TABLE 211         US: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION) 220

10.2.2    CANADA            220

10.2.2.1 Increasing government initiatives and funding for genomics research to drive market   220

TABLE 212         CANADA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)    221

TABLE 213         CANADA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION)          222

TABLE 214         CANADA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION)          222

TABLE 215         CANADA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          222

TABLE 216         CANADA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE,  2022–2029 (USD MILLION)            223

TABLE 217         CANADA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)          223

TABLE 218         CANADA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE,  2022–2029 (USD MILLION)         223

TABLE 219         CANADA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          224

TABLE 220         CANADA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)     224

10.2.3    NORTH AMERICA: RECESSION IMPACT 224

10.3       EUROPE             225

TABLE 221         EUROPE: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     225

TABLE 222         EUROPE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)    226

TABLE 223         EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION)          226

TABLE 224         EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION)          226

TABLE 225         EUROPE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          227

TABLE 226         EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE,  2022–2029 (USD MILLION)            227

TABLE 227         EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)          228

TABLE 228         EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE,  2022–2029 (USD MILLION)         228

TABLE 229         EUROPE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          229

TABLE 230         EUROPE: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)     229

10.3.1    GERMANY         229

10.3.1.1 Higher healthcare spending and improved R&D for NGS-based diagnostic tests to augment market growth     229

TABLE 231         GERMANY: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)    230

TABLE 232         GERMANY: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION)          230

TABLE 233         GERMANY: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION)    231

TABLE 234         GERMANY: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          231

TABLE 235         GERMANY: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE,  2022–2029 (USD MILLION)            231

TABLE 236         GERMANY: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)    232

TABLE 237         GERMANY: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE,  2022–2029 (USD MILLION)         232

TABLE 238         GERMANY: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          233

TABLE 239         GERMANY: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)     233

10.3.2    UK         233

10.3.2.1 Increasing biotechnology innovation centers and growing government support to fuel market growth             233

TABLE 240         UK: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)          234

TABLE 241         UK: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION)          234

TABLE 242         UK: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION)          235

TABLE 243         UK: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)     235

TABLE 244         UK: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE,  2022–2029 (USD MILLION)           235

TABLE 245        UK: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)          236

TABLE 246         UK: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE,  2022–2029 (USD MILLION)         236

TABLE 247         UK: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     237

TABLE 248         UK: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION) 237

10.3.3    FRANCE             237

10.3.3.1 Rising government investments in genomics to boost market growth       237

TABLE 249         FRANCE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)    238

TABLE 250         FRANCE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION)          239

TABLE 251         FRANCE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION)          239

TABLE 252         FRANCE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          239

TABLE 253         FRANCE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE,  2022–2029 (USD MILLION)            240

TABLE 254         FRANCE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)          240

TABLE 255         FRANCE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE,  2022–2029 (USD MILLION)         240

TABLE 256         FRANCE: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          241

TABLE 257         FRANCE: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)     241

10.3.4    ITALY   241

10.3.4.1 Favorable funding scenario in genomics research to support market growth              241

TABLE 258        ITALY: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)          242

TABLE 259         ITALY: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION)          242

TABLE 260         ITALY: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION)          243

TABLE 261         ITALY: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)     243

TABLE 262         ITALY: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE,  2022–2029 (USD MILLION)            243

TABLE 263         ITALY: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)          244

TABLE 264         ITALY: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE,  2022–2029 (USD MILLION)         244

TABLE 265         ITALY: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     244

TABLE 266         ITALY: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION) 245

10.3.5    SPAIN   245

10.3.5.1 Increased R&D funding by government to spur market growth  245

TABLE 267        SPAIN: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)          245

TABLE 268         SPAIN: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION)          246

TABLE 269         SPAIN: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION)          246

TABLE 270         SPAIN: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)     246

TABLE 271         SPAIN: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE,  2022–2029 (USD MILLION)            247

TABLE 272         SPAIN: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)          247

TABLE 273         SPAIN: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE,  2022–2029 (USD MILLION)         247

TABLE 274         SPAIN: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     248

TABLE 275         SPAIN: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION) 248

10.3.6    REST OF EUROPE           248

TABLE 276         REST OF EUROPE: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)         249

TABLE 277         REST OF EUROPE: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION) 249

TABLE 278         REST OF EUROPE: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION) 249

TABLE 279         REST OF EUROPE: GENOTYPING ASSAY MARKET, BY TECHNOLOGY,  2022–2029 (USD MILLION)       250

TABLE 280         REST OF EUROPE: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION,  BY TYPE, 2022–2029 (USD MILLION) 250

TABLE 281         REST OF EUROPE: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)      251

TABLE 282         REST OF EUROPE: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS,  BY TYPE, 2022–2029 (USD MILLION)  251

TABLE 283         REST OF EUROPE: GENOTYPING ASSAY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        252

TABLE 284        REST OF EUROPE: GENOTYPING ASSAY MARKET, BY END USER,  2022–2029 (USD MILLION)          252

10.3.7    EUROPE: RECESSION IMPACT   252

10.4       ASIA PACIFIC    253

FIGURE 41         ASIA PACIFIC: GENOTYPING ASSAY MARKET SNAPSHOT              253

TABLE 285         ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          254

TABLE 286         ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)    254

TABLE 287         ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION)    254

TABLE 288         ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION) 255

TABLE 289         ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY TECHNOLOGY,  2022–2029 (USD MILLION)       255

TABLE 290         ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION,  BY TYPE, 2022–2029 (USD MILLION) 256

TABLE 291         ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)      256

TABLE 292         ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)            256

TABLE 293        ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)          257

TABLE 294         ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)          257

10.4.1    CHINA  257

10.4.1.1 Low cost of sequencing procedures and favorable government initiatives to fuel market growth     257

TABLE 295         CHINA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)    258

TABLE 296        CHINA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION)          258

TABLE 297         CHINA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION)          259

TABLE 298         CHINA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          259

TABLE 299         CHINA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE,  2022–2029 (USD MILLION)            259

TABLE 300         CHINA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)          260

TABLE 301         CHINA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE,  2022–2029 (USD MILLION)         260

TABLE 302         CHINA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     261

TABLE 303         CHINA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION) 261

10.4.2    JAPAN  261

10.4.2.1 Launch of technologically advanced sequencing platforms to drive market              261

TABLE 304         JAPAN: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)    262

TABLE 305        JAPAN: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION)          262

TABLE 306         JAPAN: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION)          263

TABLE 307         JAPAN: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)     263

TABLE 308         JAPAN: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE,  2022–2029 (USD MILLION)            263

TABLE 309         JAPAN: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)          264

TABLE 310         JAPAN: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE,  2022–2029 (USD MILLION)         264

TABLE 311         JAPAN: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     265

TABLE 312         JAPAN: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION) 265

10.4.3    INDIA   265

10.4.3.1 Increasing research on gene expression therapies and decreasing cost of sequencing to augment market growth           265

TABLE 313        INDIA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)          267

TABLE 314         INDIA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION)          267

TABLE 315         INDIA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION)          267

TABLE 316         INDIA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)     268

TABLE 317         INDIA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE,  2022–2029 (USD MILLION)            268

TABLE 318         INDIA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)          269

TABLE 319         INDIA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE,  2022–2029 (USD MILLION)         269

TABLE 320         INDIA: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)     270

TABLE 321         INDIA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION) 270

10.4.4    REST OF ASIA PACIFIC  270

TABLE 322         REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)         271

TABLE 323         REST OF ASIA PACIFIC: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION) 271

TABLE 324         REST OF ASIA PACIFIC: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION) 271

TABLE 325         REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY TECHNOLOGY,  2022–2029 (USD MILLION)       272

TABLE 326         REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)   272

TABLE 327         REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)         273

TABLE 328         REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)     273

TABLE 329         REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        274

TABLE 330         REST OF ASIA PACIFIC: GENOTYPING ASSAY MARKET, BY END USER,  2022–2029 (USD MILLION)          274

10.4.5    ASIA PACIFIC: RECESSION IMPACT        274

10.5       LATIN AMERICA             275

TABLE 331         LATIN AMERICA: GENOTYPING ASSAY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)          275

TABLE 332         LATIN AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION) 275

TABLE 333         LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION) 276

TABLE 334         LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION) 276

TABLE 335         LATIN AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY,  2022–2029 (USD MILLION)       276

TABLE 336         LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION,  BY TYPE, 2022–2029 (USD MILLION) 277

TABLE 337         LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)      277

TABLE 338         LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS,  BY TYPE, 2022–2029 (USD MILLION)  277

TABLE 339         LATIN AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        278

TABLE 340         LATIN AMERICA: GENOTYPING ASSAY MARKET, BY END USER,  2022–2029 (USD MILLION)          278

10.5.1    BRAZIL 278

10.5.1.1 Establishment of manufacturing facilities by key players to propel market growth              278

TABLE 341         BRAZIL: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)    279

TABLE 342         BRAZIL: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION)          279

TABLE 343         BRAZIL: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION)          280

TABLE 344         BRAZIL: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          280

TABLE 345         BRAZIL: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE,  2022–2029 (USD MILLION)            280

TABLE 346         BRAZIL: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)          281

TABLE 347         BRAZIL: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE,  2022–2029 (USD MILLION)         281

TABLE 348         BRAZIL: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          282

TABLE 349         BRAZIL: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)     282

10.5.2    MEXICO             282

10.5.2.1 Favorable trade agreements and increased government support to boost market growth   282

TABLE 350         MEXICO: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)    283

TABLE 351         MEXICO: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION)          283

TABLE 352         MEXICO: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION)          284

TABLE 353         MEXICO: GENOTYPING ASSAY MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)          284

TABLE 354         MEXICO: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE,  2022–2029 (USD MILLION)            284

TABLE 355         MEXICO: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)          285

TABLE 356         MEXICO: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE,  2022–2029 (USD MILLION)         285

TABLE 357         MEXICO: GENOTYPING ASSAY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)          286

TABLE 358         MEXICO: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029 (USD MILLION)     286

10.5.3    REST OF LATIN AMERICA          286

TABLE 359         REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)         287

TABLE 360         REST OF LATIN AMERICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION) 287

TABLE 361         REST OF LATIN AMERICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION)          287

TABLE 362         REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY,  2022–2029 (USD MILLION)       288

TABLE 363         REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)   288

TABLE 364         REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)         289

TABLE 365         REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)     289

TABLE 366         REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        290

TABLE 367         REST OF LATIN AMERICA: GENOTYPING ASSAY MARKET, BY END USER,  2022–2029 (USD MILLION) 290

10.5.4    LATIN AMERICA: RECESSION IMPACT   290

10.6       MIDDLE EAST & AFRICA             291

10.6.1    INCREASING ADOPTION OF GENETIC TESTING AND RISING INCIDENCE OF CANCER TO DRIVE MARKET      291

TABLE 368         MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION)         291

TABLE 369         MIDDLE EAST & AFRICA: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION) 292

TABLE 370         MIDDLE EAST & AFRICA: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION)          292

TABLE 371         MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY TECHNOLOGY,  2022–2029 (USD MILLION)       292

TABLE 372         MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION, BY TYPE, 2022–2029 (USD MILLION)   293

TABLE 373         MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE, 2022–2029 (USD MILLION)         293

TABLE 374         MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS, BY TYPE, 2022–2029 (USD MILLION)     293

TABLE 375         MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        294

TABLE 376         MIDDLE EAST & AFRICA: GENOTYPING ASSAY MARKET, BY END USER,  2022–2029 (USD MILLION) 294

10.6.2    MIDDLE EAST & AFRICA: RECESSION IMPACT   294

10.7       GCC COUNTRIES           295

10.7.1    IMPROVED HEALTHCARE INFRASTRUCTURE AND RISE IN LIFESTYLE-RELATED DISEASES TO FUEL MARKET GROWTH           295

TABLE 377         GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY PRODUCT & SERVICE,  2022–2029 (USD MILLION) 295

TABLE 378         GCC COUNTRIES: GENOTYPING ASSAY INSTRUMENTS MARKET, BY TYPE,  2022–2029 (USD MILLION) 296

TABLE 379         GCC COUNTRIES: GENOTYPING ASSAY BIOINFORMATICS MARKET, BY TYPE,  2022–2029 (USD MILLION) 296

TABLE 380         GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY TECHNOLOGY,  2022–2029 (USD MILLION)       296

TABLE 381         GCC COUNTRIES: GENOTYPING ASSAY MARKET FOR POLYMERASE CHAIN REACTION,  BY TYPE, 2022–2029 (USD MILLION) 297

TABLE 382         GCC COUNTRIES: GENOTYPING ASSAY MARKET FOR SEQUENCING, BY TYPE,  2022–2029 (USD MILLION)      297

TABLE 383         GCC COUNTRIES: GENOTYPING ASSAY MARKET FOR CAPILLARY ELECTROPHORESIS,  BY TYPE, 2022–2029 (USD MILLION)  297

TABLE 384         GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY APPLICATION,  2022–2029 (USD MILLION)        298

TABLE 385        GCC COUNTRIES: GENOTYPING ASSAY MARKET, BY END USER,  2022–2029 (USD MILLION)          298

10.7.2    GCC COUNTRIES: RECESSION IMPACT 298

11          COMPETITIVE LANDSCAPE       300

11.1       INTRODUCTION            300

11.2       KEY PLAYER STRATEGY/RIGHT TO WIN             300

11.2.1    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENOTYPING ASSAY MARKET  300

TABLE 386         OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN GENOTYPING ASSAY MARKET  300

11.3       REVENUE ANALYSIS      301

FIGURE 42         REVENUE ANALYSIS OF KEY PLAYERS IN GENOTYPING ASSAY MARKET  (2021–2023)  302

11.4       MARKET SHARE ANALYSIS         302

FIGURE 43         MARKET SHARE ANALYSIS OF KEY PLAYERS IN GENOTYPING ASSAY MARKET (2023)  302

TABLE 387         GENOTYPING ASSAY MARKET: DEGREE OF COMPETITION              303

11.5       COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023   304

11.5.1    STARS  304

11.5.2    EMERGING LEADERS    304

11.5.3    PERVASIVE PLAYERS     304

11.5.4    PARTICIPANTS 304

FIGURE 44         GENOTYPING ASSAY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023    305

11.5.5    COMPANY FOOTPRINT: KEY PLAYERS, 2023      305

11.5.5.1 Company footprint            305

FIGURE 45         GENOTYPING ASSAY MARKET: COMPANY FOOTPRINT 305

11.5.5.2 Product & service footprint 306

TABLE 388         GENOTYPING ASSAY MARKET: PRODUCT & SERVICE FOOTPRINT      306

11.5.5.3 Technology footprint         306

TABLE 389         GENOTYPING ASSAY MARKET:  TECHNOLOGY FOOTPRINT              306

11.5.5.4 Application footprint         306

TABLE 390         GENOTYPING ASSAY MARKET: APPLICATION FOOTPRINT              306

11.5.5.5 Region footprint  307

TABLE 391         GENOTYPING ASSAY MARKET: REGION FOOTPRINT     307

11.6       COMPETITIVE EVALUATION MATRIX: STARTUPS/SMES, 2023   307

11.6.1    PROGRESSIVE COMPANIES       307

11.6.2    RESPONSIVE COMPANIES          307

11.6.3    DYNAMIC COMPANIES 307

11.6.4    STARTING BLOCKS       307

FIGURE 46         GENOTYPING ASSAY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023           308

11.6.5    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023             308

TABLE 392         GENOTYPING ASSAY MARKET: DETAILED LIST OF KEY STARTUPS/SMES           308

TABLE 393         GENOTYPING ASSAY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES        309

11.7       VALUATION & FINANCIAL METRICS      309

FIGURE 47         EV/EBITDA OF KEY VENDORS   309

FIGURE 48         YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF  KEY VENDORS           310

11.8       BRAND/PRODUCT COMPARISON          310

FIGURE 49         GENOTYPING ASSAY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS          310

11.8.1    THERMO FISHER SCIENTIFIC INC.          311

11.8.2    AGILENT TECHNOLOGIES, INC.             311

11.8.3    QIAGEN             311

11.8.4    ILLUMINA, INC. 311

11.9       COMPETITIVE SCENARIO          311

11.9.1    PRODUCT LAUNCHES, DEVELOPMENTS, AND APPROVALS       312

TABLE 394         GENOTYPING ASSAY MARKET: PRODUCT LAUNCHES, DEVELOPMENTS, AND APPROVALS, JANUARY 2020–MARCH 2024           312

11.9.2    DEALS  313

TABLE 395         GENOTYPING ASSAY MARKET: DEALS, JANUARY 2020–MARCH 2024      313

12          COMPANY PROFILES    314

12.1       KEY PLAYERS   314

(Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths, Strategic choices, and Weaknesses and Competitive threats)*

12.1.1    THERMO FISHER SCIENTIFIC INC.          314

TABLE 396         THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW              314

FIGURE 50         THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)   315

TABLE 397         THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED   315

TABLE 398         THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS,  JANUARY 2020–MARCH 2024        319

TABLE 399         THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2020–MARCH 2024     321

12.1.2    ILLUMINA, INC. 322

TABLE 400         ILLUMINA, INC.: COMPANY OVERVIEW 322

FIGURE 51         ILLUMINA, INC.: COMPANY SNAPSHOT (2023)  323

TABLE 401         ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED              323

TABLE 402         ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024      327

TABLE 403         ILLUMINA, INC.: DEALS, JANUARY 2020–MARCH 2024     328

TABLE 404         ILLUMINA, INC.: EXPANSIONS, JANUARY 2020–MARCH 2024              331

12.1.3    DANAHER CORPORATION         332

TABLE 405         DANAHER CORPORATION: COMPANY OVERVIEW         332

FIGURE 52         DANAHER CORPORATION: COMPANY SNAPSHOT (2023)              333

TABLE 406         DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED   333

TABLE 407         DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024          335

TABLE 408         DANAHER CORPORATION: DEALS, JANUARY 2020–MARCH 2024              335

12.1.4    QIAGEN             337

TABLE 409         QIAGEN: COMPANY OVERVIEW 337

FIGURE 53         QIAGEN: COMPANY SNAPSHOT (2023)  338

TABLE 410         QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 338

TABLE 411         QIAGEN: PRODUCT LAUNCHES AND DEVELOPMENTS, JANUARY 2020–MARCH 2024      340

TABLE 412         QIAGEN: DEALS, JANUARY 2020–MARCH 2024    340

12.1.5    EUROFINS SCIENTIFIC  342

TABLE 413         EUROFINS SCIENTIFIC: COMPANY OVERVIEW  342

FIGURE 54         EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2023)    343

TABLE 414         EUROFINS SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED          343

TABLE 415         EUROFINS SCIENTIFIC: PRODUCT AND SERVICE LAUNCHES, JANUARY 2020–MARCH 2024      344

TABLE 416         EUROFINS SCIENTIFIC: DEALS, JANUARY 2020–MARCH 2024              345

12.1.6    F. HOFFMANN-LA ROCHE LTD. 346

TABLE 417         F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 346

FIGURE 55         F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)              347

TABLE 418         F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED   347

TABLE 419         F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024      348

TABLE 420         F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2020–MARCH 2024      349

12.1.7    AGILENT TECHNOLOGIES, INC.             350

TABLE 421         AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 350

FIGURE 56         AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)              351

TABLE 422         AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED   351

TABLE 423         AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2020–MARCH 2024           356

12.1.8    BIO-RAD LABORATORIES, INC. 357

TABLE 424         BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW  357

FIGURE 57         BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)              358

TABLE 425         BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED   358

12.1.9    MERCK KGAA   361

TABLE 426         MERCK KGAA: COMPANY OVERVIEW    361

FIGURE 58         MERCK KGAA: COMPANY SNAPSHOT (2023)      362

TABLE 427         MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED              362

12.1.10  STANDARD BIOTOOLS 364

TABLE 428         STANDARD BIOTOOLS: COMPANY OVERVIEW 364

FIGURE 59         STANDARD BIOTOOLS: COMPANY SNAPSHOT (2023)    365

TABLE 429         STANDARD BIOTOOLS: PRODUCTS/SERVICES/SOLUTIONS OFFERED          365

12.2       OTHER PLAYERS           367

12.2.1    REVVITY            367

TABLE 430         REVVITY: COMPANY OVERVIEW            367

12.2.2    PACBIO 368

TABLE 431         PACBIO: COMPANY OVERVIEW 368

12.2.3    LUMINEX CORPORATION (A DIASORIN COMPANY)       370

TABLE 432         LUMINEX CORPORATION (A DIASORIN COMPANY): COMPANY OVERVIEW        370

12.2.4    OXFORD NANOPORE TECHNOLOGIES PLC       371

TABLE 433         OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW        371

12.2.5    GENEWIZ, INC. 372

TABLE 434         GENEWIZ, INC.: COMPANY OVERVIEW  372

12.2.6    TAKARA BIO INC.           374

TABLE 435         TAKARA BIO INC.: COMPANY OVERVIEW           374

12.2.7    BGI GROUP       375

TABLE 436         BGI GROUP: COMPANY OVERVIEW       375

12.2.8    PROMEGA CORPORATION        376

TABLE 437         PROMEGA CORPORATION: COMPANY OVERVIEW         376

12.2.9    NOVOGENE CO., LTD.  377

TABLE 438         NOVOGENE CO., LTD.: COMPANY OVERVIEW   377

12.2.10  GENSCRIPT       378

TABLE 439         GENSCRIPT: COMPANY OVERVIEW       378

12.2.11  NEW ENGLAND BIOLABS           379

TABLE 440         NEW ENGLAND BIOLABS: COMPANY OVERVIEW            379

12.2.12  PARAGON GENOMICS, INC.       379

TABLE 441         PARAGON GENOMICS, INC.: COMPANY OVERVIEW        379

12.2.13  NEOGENOMICS LABORATORIES            380

TABLE 442         NEOGENOMICS LABORATORIES: COMPANY OVERVIEW              380

12.2.14  TECAN TRADING AG     380

TABLE 443         TECAN TRADING AG: COMPANY OVERVIEW     380

12.2.15  GENOTYPIC TECHNOLOGY PVT. LTD. 381

TABLE 444         GENOTYPIC TECHNOLOGY PVT. LTD.: COMPANY OVERVIEW              381

*Details on Business overview, Products/Services/Solutions offered, Recent developments, MnM view, Key strengths, Strategic choices, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.

13          APPENDIX         382

13.1       DISCUSSION GUIDE      382

13.2       KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL             385

13.3       CUSTOMIZATION OPTIONS      387

13.4       RELATED REPORTS       387

13.5       AUTHOR DETAILS         388

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧